Type I IFN activity in serum.
- Helen M. Lazear (106036)
- Alissa Lancaster (106037)
- Courtney Wilkins (106039)
- Mehul S. Suthar (106041)
- Albert Huang (106044)
- Sarah C. Vick (106048)
- Lisa Clepper (106052)
- Larissa Thackray (106055)
- Margaret M. Brassil (106058)
- Herbert W. Virgin (5288)
- Janko Nikolich-Zugich (72930)
- Ashlee V. Moses (106061)
- Michael Gale Jr. (106064)
- Klaus Früh (106067)
- Michael S. Diamond (106070)
Publication date
January 2013
DOIAbstract
<p>WT, <i>Irf3<sup>−/−</sup>×Irf7<sup>−/−</sup></i> DKO, <i>Irf3<sup>−/−</sup>×Irf5<sup>−/−</sup>×Irf7<sup>−/−</sup></i> TKO, and <i>Ifnar<sup>−/−</sup></i> mice were infected with 10<sup>2</sup> PFU of WNV-NY or WNV-MAD and serum levels of type I IFN were measured 2 (WNV-NY) or 6 (WNV-MAD) days after infection using a bioassay. Data represent the mean ± SEM of 5 to 9 mice per group. DKO and <i>Ifnar<sup>−/−</sup></i> groups were compared to TKO by a two-way ANOVA; asterisks indicate differences that are statistically significant (****, <i>P</i><0.0001).</p
Add to ORKG